141 related articles for article (PubMed ID: 699334)
1. The quantitative determination of 5-S-cysteinyldopa and dopa in normal serum and in serum from patients with malignant melanoma by means of high-pressure liquid chromatography.
Hansson C; Edholm LE; Agrup G; Rorsman H; Rosengren AM; Rosengren E
Clin Chim Acta; 1978 Sep; 88(3):419-27. PubMed ID: 699334
[TBL] [Abstract][Full Text] [Related]
2. 5-S-Cysteinyldopa and dopa in serum during treatment with 8-methoxypsoralen and UVA light.
Hansson C; Rorsman H; Rosengren E; Tegner E
Acta Derm Venereol; 1981; 61(3):251-5. PubMed ID: 6167110
[TBL] [Abstract][Full Text] [Related]
3. Determination of DOPA, dopamine, and 5-S-cysteinyl-DOPA in plasma, urine, and tissue samples by high-performance liquid chromatography with electrochemical detection.
Ito S; Kato T; Maruta K; Fujita K; Kurahashi T
J Chromatogr; 1984 Nov; 311(1):154-9. PubMed ID: 6440898
[No Abstract] [Full Text] [Related]
4. Plasma 5-S-cysteinyldopa differentiates patients with primary and metastatic melanoma from patients with dysplastic nevus syndrome and normal subjects.
Peterson LL; Woodward WR; Fletcher WS; Palmquist M; Tucker MA; Ilias A
J Am Acad Dermatol; 1988 Sep; 19(3):509-15. PubMed ID: 3139723
[TBL] [Abstract][Full Text] [Related]
5. 5-S-cysteinyldopa, dopa, and dopamine in the kidney and some other tissues.
Agrup G; Hansson C; Rorsman H; Rosengren E
Acta Derm Venereol; 1980; 60(1):63-4. PubMed ID: 6153836
[TBL] [Abstract][Full Text] [Related]
6. Determination of urinary 5-S-cysteinyldopa by high-performance liquid chromatography.
Kågedal B; Pettersson A
J Chromatogr; 1983 Feb; 272(2):287-97. PubMed ID: 6403561
[TBL] [Abstract][Full Text] [Related]
7. Automated high-performance liquid chromatographic determination of 5-S-cysteinyl-3,4-dihydroxyphenylalanine in urine.
Kågedal B; Källberg M; Arstrand K; Hansson C
J Chromatogr; 1989 Jul; 473(2):359-70. PubMed ID: 2504759
[TBL] [Abstract][Full Text] [Related]
8. Plasma 5-S-cysteinyldopa concentrations in oculocutaneous albinism.
Nimmo JE; Hunter JA; Percy-Robb IW; Jay B; Phillips CI; Taylor WO
Acta Derm Venereol; 1985; 65(2):169-71. PubMed ID: 2408424
[TBL] [Abstract][Full Text] [Related]
9. Liquid-chromatographic determination of 5-S-L-cysteinyl-L-dopa with electrochemical detection in urine prepurified with a phenylboronate affinity gel.
Kågedal B; Pettersson A
Clin Chem; 1983 Dec; 29(12):2031-4. PubMed ID: 6416708
[TBL] [Abstract][Full Text] [Related]
10. Improved method for analysis of cysteinyldopa in human serum.
Arstrand K; Kullman A; Andersson R; Rasmuson T; Kågedal B
Scand J Clin Lab Invest; 2004; 64(6):559-64. PubMed ID: 15370461
[TBL] [Abstract][Full Text] [Related]
11. Cysteinyldopa isomers and dopa in lesions and urine of Japanese patients with malignant melanoma.
Morishima T; Tatsumi F; Fukada E; Saito M; Fujita M; Nagashima N; Hanawa S
Arch Dermatol Res; 1983; 275(2):76-9. PubMed ID: 6409012
[TBL] [Abstract][Full Text] [Related]
12. Quantitative determination of 5-S-cysteinyldopa, dopa and dopamine in the urine by means of high-performance liquid chromatography. A comparison with data obtained by means of fluorometry.
Morishima T; Saito M; Hanawa S
J Dermatol; 1981 Aug; 8(4):301-4. PubMed ID: 6795251
[No Abstract] [Full Text] [Related]
13. 5-S-cysteinyldopa in the urine of melanoma patients.
Agrup G; Agrup P; Andersson T; Falck B; Hansson JA; Jacobsson S; Rorsman H; Rosengren E; Rosengren AM
Acta Derm Venereol; 1977; 57(2):113-6. PubMed ID: 71802
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy.
Wimmer I; Meyer JC; Seifert B; Dummer R; Flace A; Burg G
Cancer Res; 1997 Nov; 57(22):5073-6. PubMed ID: 9371505
[TBL] [Abstract][Full Text] [Related]
15. Urinary 5-S-cysteinyldopa in Parkinsonism after DOPA and carbidopa.
Stewart RM; Miller S; Gunder M
Acta Derm Venereol; 1983; 63(2):97-101. PubMed ID: 6189350
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of serum 5-S-cysteinyl-dopa as a biomarker for predicting prognosis and detecting relapse in patients with advanced stage malignant melanoma.
Umemura H; Yamasaki O; Kaji T; Otsuka M; Asagoe K; Takata M; Iwatsuki K
J Dermatol; 2017 Apr; 44(4):449-454. PubMed ID: 27786364
[TBL] [Abstract][Full Text] [Related]
17. Dopa and 5-S-cysteinyldopa in the serum of albino, black, and red guinea pigs.
Hansson C; Agrup G; Rorsman H; Rosengren E
Acta Derm Venereol; 1980; 60(2):155-56. PubMed ID: 6155023
[TBL] [Abstract][Full Text] [Related]
18. Comparison of phaeomelanin and its precursor 5-S-cysteinyldopa in the serum of melanoma patients.
Wakamatsu K; Yokochi M; Naito A; Kageshita T; Ito S
Melanoma Res; 2003 Aug; 13(4):357-63. PubMed ID: 12883361
[TBL] [Abstract][Full Text] [Related]
19. Determination of 5-S-cysteinyldopa in plasma and urine using a fully automated solid-phase extraction--high-performance liquid chromatographic method for an improvement of specificity and sensitivity of this prognostic marker of malignant melanoma.
Hartleb J; Damm Y; Arndt R; Christophers E; Stockfleth E
J Chromatogr B Biomed Sci Appl; 1999 Apr; 727(1-2):31-42. PubMed ID: 10360420
[TBL] [Abstract][Full Text] [Related]
20. Plasma 5-S-cysteinyldopa correlates with tumor size in melanoma-bearing mice.
Hu F; Woodward WR; Peterson LL
J Invest Dermatol; 1988 Feb; 90(2):149-51. PubMed ID: 3123557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]